HEV 239是福建省医学分子病毒学研究中心实验室研制的一种戊型肝炎病毒(HEV)重组颗粒性蛋白疫苗,该文旨在研究HEV239蛋白疫苗在小鼠体内诱导产生特异性免疫应答的情况。将5μg HEV 239蛋白疫苗(239-Pro)、加铝佐剂疫苗(239-Vac)或加弗氏佐剂疫苗(239-CFA)肌肉注射免疫BALB/c鼠3次,第8周检测鼠血清抗HEV抗体及其亚类,同时用ELISPOT方法检测细胞毒性T细胞(CTL)应答。结果显示:239-Vac诱导的抗体滴度与239-CFA相当,高于无佐剂的239-Pro。239-Vac诱导的抗体中,IgG1/IgG2a比值显著高于239-CFA和239-Pro,主要为Th2型应答。除239-CFA之外,239-Vac和239-Pro也可诱导出一定的HEV抗原特异性I型Tc应答。提示:重组抗原HEV 239能诱导良好的抗体应答及一定的Tc1应答。
In this paper, a new eukaryotic bi-cistronic expression vector containing Hepatitis C Virus(HCV) internal ribosome entry site (IRES) expressing two foreign genes from one mRNA was constructed. The sequence starting from the 5’ untranslated region of 18nt to 32nt in HCV core coding region was cloned and then the encephalomyocarditis virus (ECMV) IRES sequence in the commercial vector pIRES was substituted to construct a new vector pCVIR. Green fluorescent protein (GFP) and Hepatitis B virus surface antigen (HBsAg) coding genes were inserted up-stream and down-stream of IRES sequence. The fluorescence intensity of GFP and HBsAg were determined by flow cytometry and ELISA respectively., thus, the expression efficiency of the two vectors, pCVIR and pIRES could be compared. The experimental results showed that the vector pCVIR could translate the GFP and HBsAg genes down-stream of its HCV IRES sequence more efficiently without impairing the expression of genes up-stream of IRES sequence than the vector pIRES.It is concluded that a new eukaryotic bi-cistronic expression vector containing HCV IRES was constructed successfully by the method described above.
